Vol. 13. Núm. 27.
Páginas 1527-1532 (Marzo 2021)

Actualización
Cáncer de útero

Uterine cancer

V. Varela PoseV. Cebey LópezM. Pérez MarteloM. Mateos GonzálezJ.F. Cueva Bañuelos
Doi : https://10.1016/j.med.2021.03.004
Opciones
Resumen

El cáncer de endometrio es el tumor ginecológico más frecuente en nuestro medio y la mayoría se diagnostican en mujeres mayores de 50 años. El cáncer de endometrio tipo 1 es el más frecuente y los factores hormonales, en concreto la exposición prolongada a estrógenos, constituye el principal factor de riesgo para el desarrollo de su lesión precursora, la hiperplasia endometrial y su posterior evolución a adenocarcinoma. El sangrado uterino anómalo es el síntoma más común y está presente en la mayoría de las pacientes con cáncer de endometrio ya en estadios precoces, por lo que ante todo sangrado anómalo debe descartarse su presencia. La prueba de imagen inicial de elección es la ecografía transvaginal y la biopsia endometrial es necesaria para su confirmación histológica. El principal factor pronóstico del cáncer de endometrio es la estadificación posquirúrgica. La cirugía constituye el pilar fundamental en el tratamiento de esta patología. La quimioterapia y la radioterapia tienen un papel importante como tratamiento adyuvante de tumores de alto riesgo y localmente avanzados. En la enfermedad metastásica, el tratamiento se basa fundamentalmente en quimioterapia paliativa, aunque en pacientes seleccionadas la hormonoterapia constituye una opción razonable.

Palabras clave
Cáncer de endometrio
Ecografía transvaginal
Biopsia endometrial
Cirugía
Quimioterapia
Radioterapia
Abstract

Endometrial cancer is the most frequent gynecologic tumor in our setting. The majority of cases are diagnosed in women older than 50 years of age. Type 1 endometrial cancer is the most frequent. Hormonal factors, specifically prolonged exposure to estrogen, are the main risk factor for developing its precursor lesion, endometrial hyperplasia, and its later progression to adenocarcinoma. Abnormal uterine bleeding is the most common symptom and occurs in the majority of patients who are already in the early stages of endometrial cancer. Therefore, its presence must be ruled out in all cases of abnormal bleeding. The initial imaging test of choice is a transvaginal ultrasound. An endometrial biopsy is necessary for its histological confirmation. The main prognostic factor of endometrial cancer is postsurgical staging. Surgery is the fundamental pillar of the treatment of this pathology. Chemotherapy and radiotherapy play an important role as adjuvant treatment of high-risk, locally advanced tumors. In metastatic disease, treatment is mainly based on palliative chemotherapy, although in select patients, hormone therapy is a reasonable option.

Keywords
Endometrial cancer
Transvaginal ultrasound
Endometrial biopsy
Surgery
Chemotherapy
Radiotherapy

Identifíquese

¿Aún no es suscriptor de la revista?

Comprar el acceso al artículo

Comprando el artículo el pdf del mismo podrá ser descargado

Teléfono para incidencias

De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h

Llamadas desde España 932 415 960
Llamadas desde fuera de España +34 932 415 960
Bibliografía
[1]
F. Bray
202103120739413528
, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin., (2018), 68 pp. 394-424
[2]
Global
202103120739413529
Cancer Observatory [Internet]. Lyon: Global Cancer Observatory; c2018-20 [consultado 20 sept 2020]. Cancer Today. Disponible en: https://gco.iarc.fr/today/online-analysis-map?
[3]
N. Colombo
2021031207394135210
2021031207394135211
, E. Preti, F. Landoni, S. Carinelli, A. Colombo, C. Marini, et al.
ESMO Guidelines Working Group. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol., (2013), 24 pp. vi33-vi38
[4]
P.T. Soliman, J.C. Oh, K.M. Schmeler, C.C. Sun, B.M. Slomovitz, D.M. Gershenson, et al.
Risk factors for young premenopausal women with endometrial cancer.
Obstet Gynecol., (2005), 105 pp. 575-580
[5]
G.D. Constantine
2021031207394135212
, G. Kessler, S. Graham, S.R. Goldstein.
Increased incidence of endometrial cancer following the women's health initiative: an assessment of risk factors.
J Womens Health (Larch)., (2019), 28 pp. 237-243
[6]
A.S. Felix
2021031207394135213
, J.L. Weissfeld, R.A. Stone, R. Bowser, M. Chivukula, R.P. Edwards, et al.
Factors associated with Type I and Type II endometrial cancer.
Cancer Causes Control., (2010), 21 pp. 1851-1856
[7]
National
2021031207394135214
Comprehensive Cancer Network (NCCN). Genetic/Familial High-Risk Assessment: colorrectal. version 1.2020. [consultado 20 sept 2020]. https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf.
[8]
J.V. Bokhman
2021031207394135215
.
Two pathogenetic types of endometrial carcinoma.
Gynecol Oncol., (1983), 15 pp. 10-17
[9]
X. Matias-Guiu
2021031207394135216
, J. Prat.
Molecular pathology of endometrial carcinoma.
Histopathology., (2013), 62 pp. 111-123
[10]
Cancer
2021031207394135217
Genome Atlas Research Network, C. Kandoth, N. Schultz, A.D. Cherniack, R. Akbani, Y. Liu, et al.
Integrated genomic characterization of endometrial carcinoma.
Nature., (2013), 497 pp. 67-73
[11]
M.A. Clarke
2021031207394135218
2021031207394135219
, B.J. Long, A. del Mar Morillo, M. Arbyn, J.N. Bakkum-Gamez, N. Wentzensen.
Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis.
JAMA Intern Med, (2018), 178 pp. 1210-1222
[12]
C.S. Chu
2021031207394135220
2021031207394135221
, L.L. Lilie, S.C. Rubin.
Gynecologic cancers. Cancer of the uterine body.
8th ed., Wolters Kluwer, pp. 1544-1589
[13]
A. Santaballa
2021031207394135222
2021031207394135223
, X. Matías-Guiu, A. Redondo, N. Carballo, M. Gil, C. Gómez, et al.
SEOM clinical guidelines for endometrial cancer (2017).
Clin Transl Oncol., (2018), 20 pp. 29-37
[14]
J.L. Walker
2021031207394135224
, M.R. Piedmonte, N.M. Spirtos, S.M. Eisenkop, J.B. Schlaerth, R.S. Mannel, et al.
Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2.
J Clin Oncol., (2009), 27 pp. 5331-5336
[15]
J.N. Barlin
2021031207394135225
2021031207394135226
, I. Puri, R.E. Bristow.
Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis.
Gynecol Oncol., (2010), 118 pp. 14-18
[16]
M.G. Del
2021031207394135227
Carmen, D.M. Boruta 2nd, J.O. Schorge.
Recurrent endometrial cancer.
Clin Obstet Gynecol., (2011), 54 pp. 266-277
[17]
B. Sorbe
2021031207394135228
2021031207394135229
, H. Andersson, K. Boman, P. Rosenberg, M. Kalling.
Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up.
Int J Gynecol Cancer., (2008), 18 pp. 803-808
[18]
V. Makker
2021031207394135230
2021031207394135231
, D. Rasco, N.J. Vogelzang, M.S. Brose, A.L. Cohn, J. Mier, et al.
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Lancet Oncol., (2019), 20 pp. 711-718
[19]
S.B. Decruze
2021031207394135232
2021031207394135233
, J.A. Green.
Hormone therapy in advanced and recurrent endometrial cancer: a systematic review.
Int J Gynecol Cancer., (2007), 17 pp. 964-978
[20]
J.V. Fiorica
2021031207394135234
, V.L. Brunetto, P. Hanjani, S.S. Lentz, R. Mannel, W. Andersen, Gynecologic Oncology Group study.
Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
Gynecol Oncol., (2004), 92 pp. 10-14
[21]
D. Lorusso
2021031207394135235
2021031207394135236
, G. Ferrandina, N. Colombo, S. Pignata, A. Pietragalla, C. Sonetto, et al.
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
Gynecol Oncol., (2019), 155 pp. 406-412
[22]
C. Aghajanian
2021031207394135237
, M.W. Sill, K.M. Darcy, B. Greer, D.S. McMeekin, P.G. Rose, et al.
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
J Clin Oncol., (2011), 29 pp. 2259-2265
[23]
A.N. Fader
2021031207394135238
2021031207394135239
, D.M. Roque, E. Siegel, N. Buza, P. Hui, O. Abdelghany, et al.
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
J Clin Oncol., (2018), 36 pp. 2044-2051